References
1. Tahrani AA, Barnett AH, Bailey CJ. Pharmacology and therapeutic
implications of current drugs for type 2 diabetes mellitus. Nat Rev
Endocrinol 2016;12:566-592
2. Wilson JM. Lessons learned from the gene therapy trial for ornithine
transcarbamylase deficiency. Mol Genet Metab 2009;96:151-157
3. Coyne DW. Influence of industry on renal guideline development. Clin
J Am Soc Nephrol 2007;2:3-7; discussion 13-14
4. Tringale KR, Marshall D, Mackey TK, Connor M, Murphy JD,
Hattangadi-Gluth JA. Types and Distribution of Payments From Industry to
Physicians in 2015. JAMA 2017;317:1774-1784
5. National Health and Nutrition Examination Survey 2017–March 2020
Prepandemic Data Files Development of Files and Prevalence Estimates for
Selected Health Outcomes. In National Health Statistics ReportsNational Center for Health S, Ed. Hyattsville, MD,
http://dx.doi.org/10.15620/cdc:106273, 2021
6. Fang M, Wang D, Coresh J, Selvin E. Undiagnosed Diabetes in U.S.
Adults: Prevalence and Trends. Diabetes Care 2022;45:1994-2002
7. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM,
Rosas SE, Del Prato S, Mathieu C, Mingrone G, Rossing P, Tankova T,
Tsapas A, Buse JB. Management of Hyperglycemia in Type 2 Diabetes, 2022.
A Consensus Report by the American Diabetes Association (ADA) and the
European Association for the Study of Diabetes (EASD). Diabetes Care
2022;45:2753-2786
8. Irwig MS, Kyinn M, Shefa MC. Financial Conflicts of Interest Among
Authors of Endocrine Society Clinical Practice Guidelines. J Clin
Endocrinol Metab 2018;103:4333-4338
9. Liu JJ, Bell CM, Matelski JJ, Detsky AS, Cram P. Payments by US
pharmaceutical and medical device manufacturers to US medical journal
editors: retrospective observational study. BMJ 2017;359:j4619
10. Inoue K, Tsugawa Y, Mangione CM, Duru OK. Association between
industry payments and prescriptions of long-acting insulin: An
observational study with propensity score matching. PLOS Medicine
2021;18:e1003645
11. Inoue K, Figueroa JF, DeJong C, Tsugawa Y, Orav EJ, Shen C, Kazi DS.
Association Between Industry Marketing Payments and Prescriptions for
PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors in the
United States. Circulation: Cardiovascular Quality and Outcomes
2021;14:e007521
12. Karanges EA, Ting N, Parker L, Fabbri A, Bero L. Pharmaceutical
industry payments to leaders of professional medical associations in
Australia: Focus on cardiovascular disease and diabetes. Aust J Gen
Pract 2020;49:151-154
13. Natures of Payment [article online], 2023. Available from
https://www.cms.gov/openpayments/natures-of-payment#:~:text=The%20Open%20Payments%20Program%20Year,medical%20supply%20or%20device%20loan.
Accessed January 17 2023
14. Open Payments [article online], 2022. Available from
https://www.cms.gov/OpenPayments/Data/Dataset-Downloads. Accessed April
13 2023
15. Brauer PR, Morse E, Mehra S. Industry Payments for Otolaryngology
Research: A Four-Year Analysis of the Open Payments Database.
Laryngoscope 2020;130:314-320
16. Ying X, Rosenblatt R, Fortune BE. Trends in Industry Payments to
Gastroenterologists and Hepatologists in the United States From 2014 to
2020. Gastroenterology 2022;163:787-791
17. Sharrak A, Nguyen T, Karabon P. Industry Research Payments to
Urologists: The First 5 Years of Open Payments Research Data. J Urol
2020;204:408-410
18. Murayama A, Kugo H, Saito Y, Saito H, Tanimoto T, Ozaki A. A
Nine-year Investigation of Healthcare Industry Payments to
Pulmonologists in the United States. Ann Am Thorac Soc 2023;
19. Murayama A, Kamamoto S, Kugo H, Saito H, Ozaki A. Research and
Nonresearch Industry Payments to Nephrologists in the United States
between 2014 and 2021. J Am Soc Nephrol 2023;
20. Feng H, Wu P, Leger M. Exploring the Industry-Dermatologist
Financial Relationship: Insight From the Open Payment Data. JAMA
Dermatol 2016;152:1307-1313
21. Annapureddy A, Murugiah K, Minges KE, Chui PW, Desai N, Curtis JP.
Industry Payments to Cardiologists. Circ Cardiovasc Qual Outcomes
2018;11:e005016
22. Murayama A, Nakano K, Kamamoto S, Sato M, Saito H, Tanimoto T, Ozaki
A. Trend in industry payments to infectious disease physicians in the
United States: a seven-year analysis of nonresearch payments from the
Open Payments Database between 2014 and 2020. Clin Microbiol Infect
2022;28:1655 e1651-1655 e1654
23. Kusumi E, Murayama A, Kamamoto S, Kawashima M, Yoshida M, Saito H,
Sawano T, Yamashita E, Tanimoto T, Ozaki A. Pharmaceutical payments to
Japanese certified hematologists: a retrospective analysis of personal
payments from pharmaceutical companies between 2016 and 2019. Blood
Cancer J 2022;12:54
24. Putman MS, Goldsher JE, Crowson CS, Duarte-Garcia A. Industry
Payments to Practicing US Rheumatologists, 2014-2019. Arthritis
Rheumatol 2021;73:2138-2144
25. Murayama A, Kamamoto S, Saito H, Tanimoto T, Ozaki A. Industry
payments to allergists and clinical immunologists in the United States
during the coronavirus disease 2019 pandemic. Ann Allergy Asthma Immunol
2022;129:635-636
26. Murayama A, Kamamoto S, Higuchi K, Shigeta H, Ozaki A. Trend in
Industry Payments to Rheumatologists in the United States During the
COVID-19 Pandemic Between 2013 and 2021. J Rheumatol 2023;50:575-577
27. Murayama A. Codes for analysis of Open Payments Database for
Endocrinology, Diabetes & Metabolism. GitHub; 2023.https://github.com/anju0007/Open-Payments-Database-Analyses/tree/ad41d9ee888a0365106c34b31cabc000103a29cc/Endocrinology%2C%20Diabetes%20%26%20Metabolism.
Updated August 2, 2023. Accessed August 2, 2023.
28. Inoue K, Blumenthal DM, Elashoff D, Tsugawa Y. Association between
physician characteristics and payments from industry in 2015-2017:
observational study. BMJ Open 2019;9:e031010
29. Ahlawat A, Narayanaswami P. Financial relationships between
neurologists and industry: The 2015 Open Payments database. Neurology
2019;92:1006-1013
30. Ellison-Barnes A, Johnson S, Gudzune K. Trends in Obesity Prevalence
Among Adults Aged 18 Through 25 Years, 1976-2018. JAMA
2021;326:2073-2074
31. Inoue K, Duru OK, Mangione CM, Tsugawa Y. Trends in Industry
Payments to Physicians for Antihyperglycemic Therapies Between 2014 and
2018. J Gen Intern Med 2021;36:2492-2494
32. Moynihan R. Key opinion leaders: independent experts or drug
representatives in disguise? BMJ 2008;336:1402-1403
33. Wright K, Meyers DE, Chisamore TM, McInnes MDF, Sismondo S, Gyawali
B, Prasad V, Booth CM. Industry Relationships With Medical Oncologists:
Who Are the High-Payment Physicians? JCO Oncology Practice
2022;18:e1164-e1169
34. Nusrat S, Syed T, Nusrat S, Chen S, Chen WJ, Bielefeldt K.
Assessment of Pharmaceutical Company and Device Manufacturer Payments to
Gastroenterologists and Their Participation in Clinical Practice
Guideline Panels. JAMA Netw Open 2018;1:e186343
35. Vanood A, Sharrak A, Karabon P, Fahim DK. Industry-Sponsored
Research Payments in Neurosurgery-Analysis of the Open Payments Database
From 2014 to 2018. Neurosurgery 2021;88:E250-e258
36. Eloy JA, Kilic S, Yoo NG, McLeod T, Svider PF, Baredes S, Folbe AJ,
Couldwell WT, Liu JK. Is Industry Funding Associated with Greater
Scholarly Impact Among Academic Neurosurgeons? World Neurosurg
2017;103:517-525
37. Murayama A. Industry-sponsored research funding to infectious
disease physicians in the United States between 2013 and 2021. Clin
Microbiol Infect 2023;
38. Kalva P, Kakkilaya A, Mekala P, Cavdar IK, Patel M, Kooner KS.
Trends and Characteristics of Industry Payments for Ophthalmology
Research From 2014 to 2020. JAMA Ophthalmol 2022;140:1105-1109
39. Ahn R, Woodbridge A, Abraham A, Saba S, Korenstein D, Madden E,
Boscardin WJ, Keyhani S. Financial ties of principal investigators and
randomized controlled trial outcomes: cross sectional study. BMJ
2017;356:i6770
40. Khan NA, Nguyen CL, Khawar T, Spencer H, Torralba KD. Association of
author’s financial conflict of interest with characteristics and outcome
of rheumatoid arthritis randomized controlled trials. Rheumatology
(Oxford) 2019;58:776-785
Table 1. Summary of annual general payments to endocrinologists
excluding ownership and royalty payments between 2014 and 2022.